Intra-arterial thrombolysis using recombinant tissue plasminogen activator (r-TPA): the optimal agent, at the optimal dose?
Thirteen patients received 15 separate courses of intra-arterial (IA) r-TPA for acute and subacute peripheral arterial thromboses. Two patients received second courses: one following rethrombosis 2 weeks after the angioplasty of a residual stenosis, the other following rethrombosis 4 months after the initially successful thrombolysis. There were 10 men and 3 women with a mean age of 75.3 yrs (+/- 12.2). The median duration of ischaemia was 18 days (range 1-60), with five patients having severe ischaemia. All patients received IA r-TPA at a dose of 0.5 mg/h for a mean period of 26.2 hrs (+/- 12.6). Angiographic evidence of lysis was seen in all patients, however, this was insufficient to reperfuse the distal limb in two patients due to absence of run-off. Early rethrombosis occurred in both of these patients (less than 24 hrs, 11 days). There were no major complications, and minor groin haematomata occurred in four patients (three of whom underwent angioplasty). A further two patients rethrombosed despite angioplasty. One was successfully retreated and remains patent 5 months later, the other underwent surgical reconstruction. A partial systemic effect was confirmed by a reduction of plasminogen and fibrinogen to 66% of initial levels, and a reduction of alpha - 2-antiplasmin to 40% of initial levels. Haemoglobin was reduced by a mean 1.28 g/dl (+/- 0.82), however no transfusions were required, and no hypotensive periods occurred. Mean ankle/brachial systolic index (ABSI) was increased by 0.43 (+/- 0.24) overall.(ABSTRACT TRUNCATED AT 250 WORDS)
Berridge
D C
DC
Department of Vascular Surgery, University Hospital, Nottingham, U.K.
Gregson
R H
RH
Hopkinson
B R
BR
Makin
G S
GS
D000368:Aged; D000369:Aged, 80 and over; D000800:Angioplasty, Balloon; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007261:Infusions, Intra-Arterial; D007511:Ischemia / Q000628:therapy*; D007866:Leg / Q000098:blood supply*; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage; D013927:Thrombosis / Q000628:therapy*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*
D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator